Standout Papers

Cancer immunoediting and resistance to T cell-based immunotherapy 2016 2026 2019 2022 1.2k
  1. Cancer immunoediting and resistance to T cell-based immunotherapy (2018)
    Jake S. O’Donnell, Michele W.L. Teng et al. Nature Reviews Clinical Oncology
  2. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease (2016)
    Jing Liu, Stephen J. Blake et al. Cancer Discovery
  3. Resistance to PD1/PDL1 checkpoint inhibition (2016)
    Jake S. O’Donnell, Georgina V. Long et al. Cancer Treatment Reviews

Immediate Impact

3 by Nobel laureates 14 from Science/Nature 53 standout
Sub-graph 1 of 23

Citing Papers

Cross-priming in cancer immunology and immunotherapy
2025 Standout
Cell death
2024 Standout
1 intermediate paper

Works of Jake S. O’Donnell being referenced

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
2018
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
2016

Author Peers

Author Last Decade Papers Cites
Jake S. O’Donnell 1390 2020 863 17 3.0k
Riccardo Mezzadra 1469 1881 1069 14 3.1k
Mengke Niu 1303 1697 954 31 3.0k
Jonathan J. Havel 1054 1844 804 14 2.6k
Viviana Cremasco 1410 1551 1159 30 3.2k
Spencer C. Wei 1922 2954 1096 13 4.4k
Michael A. Postow 1692 2927 715 18 3.9k
Audrey Lupo 1429 1615 588 44 2.7k
Todd T. Moore 1415 1806 676 17 2.8k
Yuru Meng 2696 2982 840 18 4.3k
Nadine Benhamouda 1224 1245 1004 36 2.9k

All Works

Loading papers...

Rankless by CCL
2026